Drugs / thrombomodulin alfa
thrombomodulin alfa
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05251727 | Mar 2022 → Jun 2024 | chemotherapy-induced neuropathy | Veloxis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 23 trials | ||||||
| Phase 2 | NCT04492436 | Oct 2021 → Apr 2023 | chemotherapy-induced neuropathy | Veloxis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 2 | NCT02792842 | Jul 2016 → Feb 2018 | — | Asahi Kasei Therapeutics Corporation | Completed | No outcome recorded |
| Phase 2 | NCT00487656 | Jul 2007 → May 2010 | disseminated intravascular coagulation, infectious disease with sepsis | Artisan Pharma, Inc. | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02739165 | May 2016 → Sep 2018 | idiopathic pulmonary fibrosis | Asahi Kasei Therapeutics Corporation | Completed | Missed primary |
| Phase 41 trial | ||||||
| Phase 4 | NCT01704001 | Oct 2012 → Oct 2013 | disseminated intravascular coagulation | Asahi Kasei Therapeutics Corporation | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT03517501 Comparator | Jul 2019 → Apr 2022 | infectious disease with sepsis | Asahi Kasei Pharma America Corporation | Withdrawn | No outcome recorded |
| Phase 3 | NCT01598831 Comparator | Oct 2012 → Apr 2018 | blood coagulation disease, infectious disease with sepsis | Asahi Kasei Pharma America Corporation | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-03-28 | Veloxis Pharmaceuticals | Veloxis Pharmaceuticals, Inc. Initiates Phase 1 Study of ART-123 in the U.S. and Japan veloxis.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | thrombomodulin alfa | “Thrombomodulin alfa, a recombinant human soluble thrombomodulin, has anticoagulant and antiinflammatory effects.” PMID 31917621 ↗ May 2020 |
| Known as | ART-123 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01598831 ↗ |
| Known as | recombinant human soluble thrombomodulin | “ART-123, a recombinant human soluble thrombomodulin” PMID 32965539 ↗ Sep 2020 |
| Known as | recombinant thrombomodulin | “A placebo-controlled, double-blind, randomized study of recombinant thrombomodulin (ART-123) to prevent oxaliplatin-induced peripheral neuropathy.” PMID 32965539 ↗ Sep 2020 |
| Known as | Recomodulin | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108653 ↗ |
| Known as | Recomodulin (japan only) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108653 ↗ |
| Known as | Thrombomodulin alfa (genetical recombination) | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108653 ↗ |
| Known as | Thrombomoduline alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108653 ↗ |
| Known as | Trombomodulina alfa | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108653 ↗ |
| Modality | Protein / enzyme biologic | “ART-123 (recombinant human soluble thrombomodulin)” NCT00487656 ↗ |
| Route | Intravenous | “treated with an intravenous bolus or a 15-minute infusion of thrombomodulin” PMID 31104069 ↗ May 2019 |